Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 8.9%

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shares traded down 8.9% during mid-day trading on Wednesday . The company traded as low as $21.31 and last traded at $21.33. 134,878 shares traded hands during trading, a decline of 7% from the average session volume of 145,499 shares. The stock had previously closed at $23.42.

Wall Street Analyst Weigh In

A number of research firms have recently commented on DNTH. Stifel Nicolaus started coverage on Dianthus Therapeutics in a research note on Thursday, February 15th. They set a “buy” rating and a $44.00 target price on the stock. Raymond James boosted their price objective on Dianthus Therapeutics from $34.00 to $51.00 and gave the company an “outperform” rating in a research note on Thursday, April 18th. Wedbush upped their price target on Dianthus Therapeutics from $24.00 to $33.00 and gave the company an “outperform” rating in a research report on Friday, March 22nd. Finally, Jefferies Financial Group upped their price target on Dianthus Therapeutics from $22.00 to $39.00 and gave the company a “buy” rating in a research report on Friday, March 22nd. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $42.40.

Dianthus Therapeutics Stock Performance

The business has a fifty day moving average of $25.82 and a 200 day moving average of $17.45.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Thursday, March 21st. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.40. The business had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.73 million. On average, research analysts expect that Dianthus Therapeutics, Inc. will post -1.92 EPS for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. FMR LLC bought a new position in Dianthus Therapeutics in the third quarter worth $28,961,000. Avidity Partners Management LP purchased a new stake in shares of Dianthus Therapeutics during the third quarter valued at $16,644,000. Octagon Capital Advisors LP boosted its position in shares of Dianthus Therapeutics by 15.4% during the fourth quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock valued at $5,762,000 after buying an additional 74,000 shares during the last quarter. Atlas Venture Life Science Advisors LLC purchased a new position in Dianthus Therapeutics in the third quarter worth about $3,240,000. Finally, Vestal Point Capital LP purchased a new position in Dianthus Therapeutics in the fourth quarter worth about $1,404,000. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.